Short on Competition Act
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, Short on Competition Act, changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Trade, Agriculture.
Who Benefits and How
health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section S1: 1. Short title This Act may be cited as the Short on Competition Act.
- Section idC0C577BB3B00443DB5F889894373C8FA: 2. Temporary importation of prescription drugs Section 506C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356c) is amended— by redesignating...
- Section id5FF2E9C75F324115A1BF2A2028C69D85: 506C–2. Marginally competitive drug markets If the Secretary determines under subsection (b) that a marginally competitive market exists with respect to an...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, Short on Competition Act, changes federal law or congressional policy affecting health care providers and patients.
Key Policy Areas
Healthcare, Trade, Agriculture
Primary Purpose
This bill, Short on Competition Act, changes federal law or congressional policy affecting health care providers and patients.
Policy Domains
Whole bill
Identified Gains
- health care providers and patients
Identified Costs
- federal implementing agencies
- health care providers and patients
Sponsors
Legislative Progress
In CommitteeMs. Klobuchar (for herself, Mr. Lee, Mr. Durbin, and Mr. …
Read twice and referred to the Committee on Health, Education, …
Introduced in Senate
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → The Secretary identified in the operative section
Key Definitions
Terms defined in this bill
a drug that is not a radio pharmaceutical drug product or any other product as designated by the Secretary.. (iii)the number of drugs authorized for temporary importation under section 506C(h)
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology